ongoing trials - trial from www.clinicaltrials.gov

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations - Phase 2 - Not yet recruiting

Code: NCT05641298 **Year:** 2022 **Date:** December 2022 **Author:** Aceragen

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Participants

Cystic Fibrosis|Cystic Fibrosis Pulmonary Exacerbation - 12 Years and older (Child, Adult, Older Adult)

Interventions

Drug: Sodium Fusidate|Drug: Placebo

Outcome measures

Desirability in outcome ranking (DOOR)

https://ClinicalTrials.gov/show/NCT05641298

Keywords

Sodium Fusidate; other anti-bacterial agents; Anti-Bacterial Agents; pharmacological_intervention;